Free Trial

Bristol Myers Squibb (BMY) Competitors

Bristol Myers Squibb logo
$44.86 -0.12 (-0.27%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BMY vs. AMGN, EXEL, GILD, MRNA, VRTX, ABBV, JNJ, LLY, MRK, and PFE

Should you be buying Bristol Myers Squibb stock or one of its competitors? The main competitors of Bristol Myers Squibb include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector.

Bristol Myers Squibb vs. Its Competitors

Bristol Myers Squibb (NYSE:BMY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Bristol Myers Squibb presently has a consensus price target of $56.38, suggesting a potential upside of 25.67%. Amgen has a consensus price target of $304.43, suggesting a potential upside of 6.39%. Given Bristol Myers Squibb's higher possible upside, equities research analysts clearly believe Bristol Myers Squibb is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol Myers Squibb
1 Sell rating(s)
15 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.24
Amgen
2 Sell rating(s)
12 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.24

In the previous week, Bristol Myers Squibb had 8 more articles in the media than Amgen. MarketBeat recorded 69 mentions for Bristol Myers Squibb and 61 mentions for Amgen. Amgen's average media sentiment score of 1.59 beat Bristol Myers Squibb's score of 1.27 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol Myers Squibb
48 Very Positive mention(s)
4 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Amgen
57 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Bristol Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 5.5%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Bristol Myers Squibb pays out 100.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Amgen has increased its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by insiders. Comparatively, 0.7% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Amgen has a net margin of 18.96% compared to Bristol Myers Squibb's net margin of 10.58%. Amgen's return on equity of 174.71% beat Bristol Myers Squibb's return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol Myers Squibb10.58% 80.04% 14.69%
Amgen 18.96%174.71%13.12%

Bristol Myers Squibb has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Amgen has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol Myers Squibb$48.30B1.89-$8.95B$2.4818.09
Amgen$33.42B4.61$4.09B$12.2323.40

Summary

Amgen beats Bristol Myers Squibb on 12 of the 19 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMY vs. The Competition

MetricBristol Myers SquibbMED IndustryMedical SectorNYSE Exchange
Market Cap$91.32B$3.13B$5.74B$21.64B
Dividend Yield5.51%2.36%5.61%3.51%
P/E Ratio18.0921.0776.6230.06
Price / Sales1.89446.62550.4561.08
Price / Cash7.6544.8325.8118.30
Price / Book5.559.7913.634.64
Net Income-$8.95B-$52.73M$3.29B$1.00B
7 Day Performance-3.11%2.42%1.68%0.98%
1 Month Performance-6.24%4.69%4.05%2.77%
1 Year Performance-10.31%16.24%80.58%15.15%

Bristol Myers Squibb Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMY
Bristol Myers Squibb
4.9313 of 5 stars
$44.86
-0.3%
$56.38
+25.7%
-9.0%$91.32B$48.30B18.0934,100Positive News
Dividend Announcement
AMGN
Amgen
4.6329 of 5 stars
$273.86
-0.9%
$304.43
+11.2%
-15.2%$147.50B$34.92B22.4028,000Positive News
EXEL
Exelixis
4.6851 of 5 stars
$38.99
-0.4%
$44.06
+13.0%
+49.8%$10.49B$2.17B18.741,147
GILD
Gilead Sciences
4.952 of 5 stars
$112.37
-1.2%
$115.39
+2.7%
+34.0%$139.44B$28.75B22.3917,600Positive News
MRNA
Moderna
4.4691 of 5 stars
$23.67
+0.7%
$41.81
+76.7%
-59.6%$9.20B$3.24B-3.145,800
VRTX
Vertex Pharmaceuticals
4.9151 of 5 stars
$393.99
-0.1%
$496.05
+25.9%
-17.6%$101.08B$11.02B28.186,100Positive News
Analyst Revision
ABBV
AbbVie
4.7746 of 5 stars
$216.83
-0.7%
$218.76
+0.9%
+15.3%$383.24B$58.33B103.3155,000Trending News
Analyst Forecast
Analyst Revision
JNJ
Johnson & Johnson
4.7489 of 5 stars
$177.21
-0.5%
$176.29
-0.5%
+6.1%$426.65B$90.63B18.95138,100Trending News
Analyst Upgrade
LLY
Eli Lilly and Company
4.9985 of 5 stars
$747.62
-1.0%
$941.35
+25.9%
-18.0%$707.50B$53.26B48.8647,000Trending News
Analyst Downgrade
MRK
Merck & Co., Inc.
4.9993 of 5 stars
$81.25
-0.9%
$107.44
+32.2%
-31.3%$202.94B$64.17B12.5275,000Positive News
PFE
Pfizer
4.9852 of 5 stars
$23.94
+0.3%
$28.12
+17.5%
-18.3%$136.08B$63.63B12.7381,000Trending News
Analyst Upgrade
Options Volume

Related Companies and Tools


This page (NYSE:BMY) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners